New Drugs Approved

COVID-19 and the Long-Term Risk of Autoimmune Disorders

COVID-19 and the Long-Term Risk of Autoimmune Disorders

What Did the Research Discover? Researchers investigated whether COVID-19 infection increases the long-term risk of developing autoimmune and autoinflammatory connective tissue disorders. The study included 6,912,427 participants in South Korea, with 3,145,388 individuals who had COVID-19 and 3,767,039 who did not. The participants were followed for at least 180...

New Insights on COVID-19: Why Snakes Aren’t the Source

New Insights on COVID-19: Why Snakes Aren’t the Source

What Did the Research Discover? Scientists investigated how the 2019-nCoV coronavirus (now known as SARS-CoV-2) spread to humans and whether previous claims about its origins were accurate. Earlier studies suggested that snakes were an intermediate host and that the virus had genetic sequences similar to HIV-1, raising concerns about its origin. To test these...

FDA Approves ORSERDU for Advanced Breast Cancer on January 27, 2023

FDA Approves ORSERDU for Advanced Breast Cancer on January 27, 2023

What is ORSERDU prescribed for?   For treatment of postmenopausal women or adult men, with ERpositive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy What is the name of the drug and what does it do?  ORSERDU (generic name: elacestrant), pronounced...

FDA Approves Sohonos for Fibrodysplasia Ossificans Progressiva on August 16, 2023

FDA Approves Sohonos for Fibrodysplasia Ossificans Progressiva on August 16, 2023

What is Sohonos prescribed for?   Sohonos is prescribed to reduce the volume of new heterotopic ossification in adults and pediatric patients (aged 8 years and older for females and 10 years and older for males) with fibrodysplasia ossificans progressiva. What is the name of the drug and what does it do? Sohonos, pronounced so-ho-nos, (generic name:...

FDA Approves Izervay for Treating Severe  Age-related Macular Degeneration August 4, 2023

FDA Approves Izervay for Treating Severe  Age-related Macular Degeneration August 4, 2023

What is Izervay prescribed for?   Izervay is prescribed to treat geographic atrophy (GA) secondary to age-related macular degeneration. What is the name of the drug and what does it do? Izervay, pronounced  EYE-ZER-VEY, (generic name: avacincaptad pegol) is a prescription medication approved for the treatment of geographic atrophy (GA), which is a...